Search Medical Condition
Please enter condition
Please choose location

Dalian, China Clinical Trials

A listing of Dalian, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (63) clinical trials

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

This is a randomized, open, 1:1 parallel controlled, multi-center, non-inferiority clinical study.

Phase

0.0 miles

Learn More »

Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma

Treatment options for advanced HCC are limited due to patients' poor condition, advanced stage, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy. Trans-catheter embolization (TAE) is a safe locoregional treatment for advanced HCC and p53 gene has multiple anticancer functions, and both methods do not have ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

Phase

0.0 miles

Learn More »

Test Albuvirtide in Experienced Patients

This is a 48-week, randomized, controlled, open-label, multicenter study of the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1 infected adults who are failing their first antiretroviral regimen and have HIV-1 RNA levels >= 1000 copies/mL at screening. Subjects meeting inclusion criteria are randomized in a 1:1 ratio to ...

Phase

0.0 miles

Learn More »

BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

This study is a prospective, multicentred randomized controlled trial, planning to enroll 430 subjects and randomize 1:1 to study group and control group. All subjects will accepte clinical evaluation at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year post procedure. All subjects will accepte angiographic ...

Phase N/A

0.0 miles

Learn More »

The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial

The efficacy and safety of Butylphthalide Soft Capsules (En Bi Pu, NBP)in acute ischemic stroke has been demonstrated in China recently. Its role in secondary prevention of ischemic stroke need to be evaluated.

Phase

0.0 miles

Learn More »

REALM China Extension Study

The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study

Phase N/A

0.0 miles

Learn More »

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2. The study will ...

Phase N/A

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC). The primary hypothesis of this study is that overall survival is prolonged in participants who receive pembrolizumab ...

Phase

0.0 miles

Learn More »